Tango Therapeutics has appointed Robert Azelby to its Board of Directors. Azelby brings more than 30 years of experience in executive management, commercial product launches, and corporate governance, and currently serves on the boards of ADC Therapeutics, Autolus Therapeutics, and Cardinal Health. He previously served as President and CEO of Eliem Therapeutics and as CEO and board member of Alder BioPharmaceuticals. Tango is advancing its investigational PRMT5 inhibitor, Vopimetostat, through late-stage development for pancreatic cancer. Shares of Tango closed Monday at $28.50, up 1.89%, and were trading at $28.49 in the pre-market.
Tango Therapeutics IncAppointment of experienced executive Robert Azelby to board strengthens governance and strategic oversight.
ADC Therapeutics SA
Autolus Therapeutics Ltd
Cardinal Health Inc